Star Update Podcast - Cardiology News Summaries

Nov 29 2024 180 ep. 2 mins 1
Star Update Podcast - Cardiology News Summaries artwork

Want to hear the latest in cardiology research, reviews, and perspectives? Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Our summaries are available monthly.

  Health & Fitness
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Contemporary Use of β-Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis

Nov 29 2024 2 mins  
Contemporary Use of β-Blockers in Heart Failure Patients With and Without Atrial Fibrillation: A Nationwide Database Analysis Clin Pharmacol Ther. 2024 Nov 18. doi: 10.1002/cpt.3496. Abstract Evidence of the effectiveness of β-blockers in heart failure (HF) and atrial fibrillation (AF) in a contemporary cohort is controversial. This study investigated the association between the

Guideline-directed medical therapy improves cell viability in an iPSC-derived cardiomyocyte hypoxia injury model

Nov 29 2024 3 mins  
Guideline-directed medical therapy improves cell viability in an iPSC-derived cardiomyocyte hypoxia injury model https://doi.org/10.1161/circ.150.suppl_1.4147229 Abstract Introduction: Beta blockers, renin-angiotensin-aldosterone antagonists, and mineralocorticoid antagonists are mainstays of current guideline-directed medical therapy (GDMT) in heart failure with reduced ejection

Exploring The Risks And Benefits of Upstream Loading of P2Y12 inhibitors In Acute Coronary Syndrome Patients

Nov 29 2024 3 mins  
Exploring The Risks And Benefits of Upstream Loading of P2Y12 inhibitors In Acute Coronary Syndrome Patients https://doi.org/10.1161/circ.150.suppl_1.4139561 Abstract Background: Acute coronary syndrome (ACS) is the leading cause of heart disease, resulting in over 300,000 deaths annually. The 2014 ACC/AHA guideline recommends a loading dose of a P2Y12 receptor inhibitor prior to P

Ticagrelor monotherapy the way forward after Percutaneous Coronary Interventions: An updated meta-analysis

Nov 29 2024 3 mins  
Ticagrelor monotherapy the way forward after Percutaneous Coronary Interventions: An updated meta-analysis https://doi.org/10.1161/circ.150.suppl_1.4124335 Abstract Background: With the advent of newer generation drug eluting stents, the chorus for shortening the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary interventions (PCI) is getting louder and lo

Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus

Oct 30 2024 3 mins  
Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus J Assoc Physicians India . 2024 Oct;72(10):83-90. doi: 10.59556/japi.72.0715. Abstract Background: Management of essential hypertension (HTN) remains challenging, with contemporary control being achieved in <1/10 of the cases, especially when aligned with the recently updated guidelines of Amer

Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes. A Systematic Review and Network Meta-Analysis

Oct 30 2024 4 mins  
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes. A Systematic Review and Network Meta-Analysis JAMA Cardiol. Published online October 9, 2024. doi:10.1001/jamacardio.2024.3216 Abstract Importance : The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneou

Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022)

Oct 30 2024 5 mins  
Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022) https://doi.org/10.26442/00403660.2024.09.202848 Abstract Background. Arterial hypertension remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular diseas

Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review

Oct 30 2024 1 mins  
Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review Thromb J . 2024 Oct 11;22(1):90. doi: 10.1186/s12959-024-00658-9 Abstract Recent years have seen ticagrelor, a potent P2Y12 inhibitor, emerge as a significant advancement in the peri-thrombolytic management of patients with ST-segment elevation myo

Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial

Sep 29 2024 2 mins  
Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial JAMA 2024 Sep 2:e2417921. doi: 10.1001/jama.2024.17921 Abstract Importance: There are concerns that pulmonary vein isolation for atrial fibrillation may have a profound placebo effect, but no double-blind randomized clinical trials have been conducted. Objectiv

2024 ESC Guidelines for Management of Chronic Coronary Syndromes: Key Points

Sep 29 2024 7 mins  
2024 European Society of Cardiology Guidelines for Management of Chronic Coronary Syndromes: Key Points European Heart Journal, ehae177, https://doi.org/10.1093/eurheartj/ehae177 The key points to remember from the 2024 European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndromes (CCS) are: · The term chronic coronary syndromes describes the c